China (Mainland)
Fmoc-8-amino-3,6-dioxaoctanoyl-8-amino-3,6-dioxaoctanoic acid CAS NO.560088-89-3
- FOB Price: USD: /Kilogram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
good(1-100)Kilogram
- Product Details
Keywords
- Fmoc-AEEA-AEEA
- Semaglutide intermediate
- Fmoc-AEEAc-AEEAc-OH
Quick Details
- ProName: Fmoc-8-amino-3,6-dioxaoctanoyl-8-amino...
- CasNo: 560088-89-3
- Molecular Formula: C27H34N2O9
- Appearance: Clear or yellowish viscous liquid
- Application: medical intermediate
- DeliveryTime: available goods in stock
- PackAge: inside:double PE bag Outside: paper ...
- Port: any port in China
- ProductionCapacity: more than 50 Kilogram/Month
- Purity: ≥95%
- Transportation: CIF by air or DAP by courier, FOB,EX w...
- LimitNum: 1 Gram
- Moisture Content: not more than 1.0%
- Impurity: not more than 0.5
Superiority
We have produced this product many years and now got scale production .Purity can reach more than 98%.
The Corporation's main product are high purity single molecular PEG series derivatives, hydroxyproline series derivatives, polypeptide long acting drug side chain and its intermediates (including Semaglutide side chain, liraglutide side chain, Degu insulin side chain, long-acting production hormone, etc.), and short peptide drugs modified side chains (semaglutide dipeptide, tetrapeptide).
Our company is working with innovative pharmaceutical companies to build a platform for research and development of polypeptide long-acting drugs, and is committed to building a systematic and diverse long-acting side chain library, establishing molecular blocks of polypeptide long-acting side chains, and providing various development solutions for customers to develop polypeptide long-acting drugs.
Details
We have produced this product many years and now got scale production .Purity can reach more than 98%.
The Corporation's main product are high purity single molecular PEG series derivatives, hydroxyproline series derivatives, polypeptide long acting drug side chain and its intermediates (including Semaglutide side chain, liraglutide side chain, Degu insulin side chain, long-acting production hormone, etc.), and short peptide drugs modified side chains (semaglutide dipeptide, tetrapeptide).
Our company is working with innovative pharmaceutical companies to build a platform for research and development of polypeptide long-acting drugs, and is committed to building a systematic and diverse long-acting side chain library, establishing molecular blocks of polypeptide long-acting side chains, and providing various development solutions for customers to develop polypeptide long-acting drugs.